Promising Therapy Aims to Reduce Brain Inflammation in Parkinson’s Disease

ZyVersa Therapeutics is developing a new therapy, IC 100, that may help reduce chronic brain inflammation linked to Parkinson’s disease. The therapy works by blocking a key protein called ASC, which plays a role in triggering inflammation in the brain’s immune cells (called microglia). Reducing Inflammation and Toxic Protein Buildup In Parkinson’s disease, toxic clumps of a protein called alpha-synuclein can build up in the brain. This is believed to contribute to the loss of dopamine-producing neurons that are critical for movement and coordination. The new study found that IC 100 was able to reduce the buildup of this harmful protein and prevent inflammation from being triggered and sustained in the brain. Why This Matters Inflammasomes are multi-protein complexes that help start the body’s inflammatory response. In Parkinson’s, ongoing activation of inflammasomes may lead to further damage in the brain. The researchers found that ASC, a key part of the inflammasome, was more active in the brains of people with Parkinson’s and Lewy body dementia, another condition involving toxic alpha-synuclein buildup. Early Results Are Encouraging The study, published in npj Parkinson’s Disease, showed that when mouse immune cells were exposed to protein samples from people with Parkinson’s or Lewy body dementia, the inflammasomes became active. However, when the cells were also treated with IC 100, the inflammatory response was significantly reduced. This effect was also seen when researchers introduced toxic alpha-synuclein into brain immune cells — IC 100 appeared to help reduce the buildup, possibly by improving how the cells cleared the protein. A Potential Step Toward a Disease-Modifying Therapy “These findings suggest that targeting ASC and inflammasomes could help reduce both inflammation and protein buildup in the brain,” said Dr. Robert W. Keane, the study’s lead author from the University of Miami. ZyVersa’s CEO, Stephen Glover, said the company is preparing to begin proof-of-concept studies in animal models later this year. Funded by the Michael J. Fox Foundation The study was supported by a grant from The Michael J. Fox Foundation for Parkinson’s Research. Researchers from ZyVersa and the University of Miami collaborated on this early-stage investigation into IC 100. While IC 100 is still in the early stages of development and more research is needed, these results offer a sign that reducing inflammation in the brain may help slow or modify the progression of Parkinson’s disease.